Abstract
Background
Down syndrome (DS) is a common chromosomal disease resulting in neurodegeneration. Cognitive competence has been assessed among adults with DS using various methods because DS patients have a tendency to develop Alzheimer’s disease (AD) after middle age. However, research describing cognitive assessments in DS children is not as many as in DS adults, let alone with regard to performed analyses to determine factors that predict cognitive assessments. In this study, we evaluated the Gesell Developmental Schedules (GDS) scores and their associations with the relevant biochemical indicators and demographic factors in DS children.
Methods
All the subjects underwent GDS testing. The plasma amyloid-β (Aβ) peptide and serum vitamin A (VA) values were measured with enzyme-linked immunosorbent assay and high-performance liquid chromatography, and in the meanwhile, the demographic information of the subjects was collected.
Results
Forty-six DS children were recruited for this study. The GDS scores of children with DS were lower than those in children without DS. The plasma Aβ40 and Aβ42 levels were negatively associated with the GDS scores. Moreover, the GDS scores of the non-VA deficiency (NVAD) group were significantly higher than those of the VA deficiency (VAD) group. Certain demographic characteristics, such as the paternal labor intensity and paternal educational status, were relevant factors with regard to the GDS scores of the DS children.
Conclusions
This study determined that DS children exhibited abnormal GDS scores which indicated developmental delay of children with DS; the levels of plasma Aβ40, Aβ42 and serum VA were influential biochemical indicators and the paternal labor intensity and educational status were related demographic factors.
Acknowledgments
The authors thank all participants and their parents in this study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This research was supported by National Natural Science Foundation of China (81600690, Funder Id: http://dx.doi.org/10.13039/501100001809).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Wu J, Morris JK. The population prevalence of Down’s syndrome in England and Wales in 2011. Eur J Hum Genet 2013;21:1016–9.10.1038/ejhg.2012.294Search in Google Scholar
2. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down’s syndrome. Lancet Neurol 2010;9:623–33.10.1016/S1474-4422(10)70112-5Search in Google Scholar
3. Gardiner K, Herault Y, Lott IT, Antonarakis SE, Reeves RH, et al. Down syndrome: from understanding the neurobiology to therapy. J Neurosci 2010;30:14943–5.10.1523/JNEUROSCI.3728-10.2010Search in Google Scholar PubMed PubMed Central
4. Tenneti N, Dayal D, Sharda S, Panigrahi I, Didi M, et al. Concentrations of leptin, adiponectin and other metabolic parameters in non-obese children with Down syndrome. J Pediatr Endocrinol Metab 2017;30:831–7.10.1515/jpem-2016-0422Search in Google Scholar PubMed
5. Zeng J, Chen L, Wang Z, Chen Q, Fan Z, et al. Marginal vitamin A deficiency facilitates Alzheimer’s pathogenesis. Acta Neuropathol 2017;133:967–82.10.1007/s00401-017-1669-ySearch in Google Scholar PubMed
6. Kins S, Beyreuther K. Teasing out the tangles. Nat Med 2006;12:764–5; discussion 765.10.1038/nm0706-764Search in Google Scholar PubMed
7. Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci 2007;8:755–65.10.1038/nrn2212Search in Google Scholar PubMed
8. Goodman AB, Pardee AB. Evidence for defective retinoid transport and function in late onset Alzheimer’s disease. Proc Natl Acad Sci U S A 2003;100:2901–5.10.1073/pnas.0437937100Search in Google Scholar PubMed PubMed Central
9. Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, et al. Increased CSF APPs-alpha levels in patients with Alzheimer disease treated with acitretin. Neurology 2014;83:1930–5.10.1212/WNL.0000000000001017Search in Google Scholar PubMed
10. Wang Y, Zhang Y, Ji L, Hu Y, Zhang J, et al. Prenatal and postnatal exposure to organophosphate pesticides and childhood neurodevelopment in Shandong, China. Environ Int 2017;108:119–26.10.1016/j.envint.2017.08.010Search in Google Scholar PubMed
11. Jin X, Sun Y, Jiang F, Ma J, Morgan C, et al. “Care for Development” intervention in rural China: a prospective follow-up study. J Dev Behav Pediatr 2007;28:213–8.10.1097/dbp.0b013e31802d410bSearch in Google Scholar PubMed
12. de Onis M, Onyango AW, Van den Broeck J, Chumlea WC, Martorell R. Measurement and standardization protocols for anthropometry used in the construction of a new international growth reference. Food Nutr Bull 2004;25(1 Suppl):S27–36.10.1177/15648265040251S105Search in Google Scholar PubMed
13. Chen K, Li TY, Chen L, Qu P, Liu YX. Effects of vitamin A, vitamin A plus iron and multiple micronutrient-fortified seasoning powder on preschool children in a suburb of Chongqing, China. J Nutr Sci Vitaminol 2008;54:440–7.10.3177/jnsv.54.440Search in Google Scholar PubMed
14. Zhao W, Cong L. [Physical activity evaluation: metabolic equivalent intensity levels and evaluation of different physical activity]. Wei sheng yan jiu=J Hyg Res 2004;33:246–9.Search in Google Scholar
15. Dror R, Malinger G, Ben-Sira L, Lev D, Pick CG, et al. Developmental outcome of children with enlargement of the cisterna magna identified in utero. J Child Neurol 2009;24:1486–92.10.1177/0883073808331358Search in Google Scholar PubMed
16. WHO. Indicators for Assessing Vitamin A Deficiency and Their Application.pdf.Search in Google Scholar
17. Ghezzo A, Salvioli S, Solimando MC, Palmieri A, Chiostergi C, et al. Age-related changes of adaptive and neuropsychological features in persons with Down Syndrome. PLoS One 2014;9:e113111.10.1371/journal.pone.0113111Search in Google Scholar PubMed PubMed Central
18. Doyle LW, Davis PG, Schmidt B, Anderson PJ. Cognitive outcome at 24 months is more predictive than at 18 months for IQ at 8–9 years in extremely low birth weight children. Early Hum Dev 2012;88:95–8.10.1016/j.earlhumdev.2011.07.013Search in Google Scholar PubMed
19. Hack M, Taylor HG, Drotar D, Schluchter M, Cartar L, et al. Poor predictive validity of the Bayley Scales of Infant Development for cognitive function of extremely low birth weight children at school age. Pediatrics 2005;116:333–41.10.1542/peds.2005-0173Search in Google Scholar PubMed
20. Chen K, Zhang X, Wei XP, Qu P, Liu YX, et al. Antioxidant vitamin status during pregnancy in relation to cognitive development in the first two years of life. Early Hum Dev 2009;85:421–7.10.1016/j.earlhumdev.2009.02.001Search in Google Scholar PubMed
21. Chapman RS. Language learning in Down syndrome: the speech and language profile compared to adolescents with cognitive impairment of unknown origin. Downs Syndr Res Pract 2006;10:61–6.10.3104/reports.306Search in Google Scholar PubMed
22. Tedeschi AS, Roizen NJ, Taylor HG, Murray G, Curtis CA, et al. The prevalence of congenital hearing loss in neonates with Down syndrome. J Pediatr 2015;166:168–71.10.1016/j.jpeds.2014.09.005Search in Google Scholar PubMed
23. Hardy J. Alzheimer’s disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 2006;9(3 Suppl):151–3.10.3233/JAD-2006-9S317Search in Google Scholar
24. Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984;122:1131–5.10.1016/0006-291X(84)91209-9Search in Google Scholar
25. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, et al. Amyloid A4 protein and its precursor in Down’s syndrome and Alzheimer’s disease. N Engl J Med 1989;320:1446–52.10.1056/NEJM198906013202203Search in Google Scholar PubMed
26. Head E, Helman AM, Powell D, Schmitt FA. Down syndrome, beta-amyloid and neuroimaging. Free Radic Biol Med 2018;114:102–9.10.1016/j.freeradbiomed.2017.09.013Search in Google Scholar PubMed PubMed Central
27. Annus T, Wilson LR, Hong YT, Acosta-Cabronero J, Fryer TD, et al. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement 2016;12:538–45.10.1016/j.jalz.2015.07.490Search in Google Scholar PubMed PubMed Central
28. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, et al. Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides. Nat Med 1997;3:1016–20.10.1038/nm0997-1016Search in Google Scholar PubMed
29. Jiang W, Guo M, Gong M, Chen L, Bi Y, et al. Vitamin A bio-modulates apoptosis via the mitochondrial pathway after hypoxic-ischemic brain damage. Mol Brain 2018;11:14.10.1186/s13041-018-0360-0Search in Google Scholar PubMed PubMed Central
30. Lopes da Silva S, Vellas B, Elemans S, Luchsinger J, Kamphuis P, et al. Plasma nutrient status of patients with Alzheimer’s disease: Systematic review and meta-analysis. Alzheimers Dement 2014;10:485–02.10.1016/j.jalz.2013.05.1771Search in Google Scholar PubMed
31. Chavez CJ, Ortega P, Leal J, D’Escrivan A, Gonzalez R, et al. [Vitamin A deficiency and nutritional status in patients with Down’s syndrome]. An Pediatr 2010;72:185–90.Search in Google Scholar
32. Evans DW, Uljarevic M. Parental education accounts for variability in the IQs of probands with Down syndrome: a longitudinal study. Am J Med Genet A 2018;176:29–33.10.1002/ajmg.a.38519Search in Google Scholar PubMed
©2020 Walter de Gruyter GmbH, Berlin/Boston
